市场调查报告书
商品编码
1467746
2024-2032年按产品类型、人口统计(成人、儿童)、适应症、最终用户(诊断/诊所、重症监护病房、家庭医疗保健)和地区分類的下一代糖尿病治疗和药物传输市场Next Generation Diabetes Therapy and Drug Delivery Market by Product Type, Demographic (Adult Population, Child Population ), Indication, End User (Diagnostic/Clinics, Intensive Care Units, Home Healthcare), and Region 2024-2032 |
IMARC Group年,全球下一代糖尿病治疗和药物输送市场规模达到98亿美元。糖尿病(尤其是第 2 型糖尿病)盛行率的上升、技术的不断进步以及老年人口的不断增长是推动市场发展的一些关键因素。
下一代糖尿病治疗和药物输送程序的重点是以微创方式将胰岛素引入患者体内,以减少频繁使用针头引起皮肤刺激的风险。这种对患者友善的方法旨在透过利用穿戴式感测器、微针和吸入胰岛素等创新技术来有效管理疾病,同时降低医疗成本。连续血糖监测系统 (CGMS)、人工胰臟和胰岛素贴片等先进疗法也被用来改善血糖水平管理,从而最大限度地降低糖尿病相关併发症的风险。此外,该程序还可以轻鬆计算剂量体积,即时检查血糖水平,并将胰岛素无痛地输送到体内,有助于维持给药时间。这种疗法和药物传递实践的一些优点包括改善患者的治疗效果、提高治疗效率以及最大限度地减少患者的糖尿病管理负担,从而製定更有针对性的治疗计划。
全球市场的主要驱动力是大众中糖尿病(尤其是第 2 型糖尿病)盛行率的上升。这可以归因于不健康饮食的增加、久坐的生活方式和体力活动的减少。与此一致的是,根据个人需求、生活方式和治疗目标对个人化和以患者为中心的护理的需求不断增加,导致产品的采用率更高。此外,不断的技术进步,例如智慧胰岛素笔、闭环系统和副作用较少的植入式设备的开发,正在为市场提供动力。除此之外,个人对微创和无痛治疗选择的日益重视也是市场成长的重要诱导因素。医疗保健支出的增加以及对基于价值的医疗保健解决方案的更多关注进一步推动了市场。然而,发展中地区日益增长的成本限制、缺乏意识和产品变异性较小是市场成长的主要限制因素。相反,有关预防性医疗保健和早期干预的有利政府倡议和报销政策的实施正在为市场创造积极的前景。除此之外,越来越多的老年人口更容易罹患慢性病,这对市场产生了有利的影响。促进市场发展的其他一些因素包括快速城市化、对传统糖尿病治疗相关併发症的认识不断提高、远距医疗和数位医疗解决方案的日益采用、可支配收入水平的提高以及主要参与者进行的广泛研发( R&D)活动。
The global next generation diabetes therapy and drug delivery market size reached US$ 9.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 33.5 Billion by 2032, exhibiting a growth rate (CAGR) of 14.23% during 2024-2032. The rising prevalence of diabetes, particularly type-2 diabetes, continual technological advancements, and the growing geriatric population represent some of the key factors driving the market.
Next generation diabetes therapy and drug delivery procedure focuses on the introduction of insulin into the patient's body in a minimally invasive manner to reduce the risk of skin irritation from frequent needle usage. This patient-friendly approach aims to effectively manage the disease while reducing healthcare costs by utilizing innovative technologies including wearable sensors, micro-needles, and inhalable insulin. Advanced therapies, such as continuous glucose monitoring systems (CGMS), artificial pancreas, and insulin patches, are also employed to improve blood sugar level management that minimize the risks of diabetic-related complications. In addition, the procedure facilitates easy calculation of the dose volume, checking the blood glucose levels in real-time, and delivers insulin into the body painlessly, which, in turn, helps to maintain the dosage time. Some of the advantages of this therapy and drug delivery practice includes improved patient outcomes, enhanced treatment efficiency, and minimized burden of diabetes management for patients, leading to more targeted treatment plans.
The global market is primarily driven by the rising prevalence of diabetes, particularly type-2 diabetes, among the masses. This can be attributed to the increasing consumption of unhealthy diets, sedentary lifestyles and reduced physical activity. In line with this, the augmenting demand for personalized and patient-centric care according to individual needs, lifestyle, and treatment goals is resulting in a higher product uptake. Moreover, continual technological advancements, such as the development of smart insulin pens, closed-loop systems, and implantable devices with fewer side effects, is providing an impetus to the market. In addition to this, the increasing emphasis on minimally invasive and pain-free treatment options among individuals is also acting as a significant growth-inducing factor for the market. The market is further driven by the increasing healthcare expenditure, along with an enhanced focus on value-based medical care solutions. However, the growing cost restrains, lack of awareness and less variability in products in the developing regions are acting as major growth-restraining factors for the market. Conversely, the implementation of favorable government initiatives and reimbursement policies regarding preventive healthcare and early intervention is creating a positive outlook for the market. Apart from this, the growing geriatric population that is more susceptible to developing chronic diseases is impacting the market favorably. Some of the other factors contributing to the market include rapid urbanization, increasing awareness regarding the associated complications of traditional diabetes treatment, rising adoption of telehealth and digital health solutions, inflating disposable income levels and extensive research and development (R&D) activities conducted by key players.
IMARC Group provides an analysis of the key trends in each segment of the global next generation diabetes therapy and drug delivery market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, demographic, indication, and end user.
Inhalable Insulin
Oral Insulin
Insulin Patches
CGM Systems
Artificial Pancreas
The report has provided a detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the product type. This includes inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. According to the report, CGM systems represented the largest segment.
Adult Population (>14 Years)
Child Population (14 Years)
The report has provided a detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the demographic. This includes adult population (>14 years) and child population (14 years). According to the report, adult population (>14 years) represented the largest segment.
Type 1 diabetes
Type 2 diabetes
The report has provided a detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the indication. This includes type 1 diabetes, type 2 diabetes. According to the report, type 2 diabetes represented the largest segment.
Diagnostic/Clinics
Intensive Care Units (ICUs)
Home Healthcare
A detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the end user has also been provided in the report. This includes diagnostic/clinics, intensive care units (ICUs), and home healthcare. According to the report, diagnostic/clinics accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for next generation diabetes therapy and drug delivery. Some of the factors driving the North America next generation diabetes therapy and drug delivery market included the aging population, continual technological advancements, high healthcare expenditure, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global next generation diabetes therapy and drug delivery market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Dexcom Inc., Eli Lilly and Company, Enteris BioPharma Inc. (Swk Holdings Corporation), GlySens Incorporated, MannKind Corporation, Medtronic plc, Sanofi, Senseonics, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.